9 results
Primary• To evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-…
The aim of this study is to evaluate the effect of a single oral dose of TW001 on oxidative stress and pharmacokinetics with and without food. Dosing with an oral solution is considered to have major advantages over iv dosing in a chronic condition…
2.1 Primary objectiveTo assess the rate of no progression (NPR) at 8 weeks following treatment with the combination of gefitinib and fulvestrant in EGFR mutated patients who failed previous treatment with reversible EGFR TKI*s (gefitinib or…
The primary objective of this study is to evaluate the disease control rate (DCR; confirmed complete response (CR) or partial response (PR), or stable disease (SD)) of gefitinib using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.…
Primary objectives: 1) Phase Ib: To estimate the MTD or RP2D of INC280 in combination with gefitinib in NSCLC patients who have c-MET dysregulation. 2) Phase II: To estimate overall clinical activity of INC280 in combination with gefitinib in NSCLC…
To evaluate the long-term safety of FAB122 in patients with ALS.
Primary objective:The main objective of the present trial are:• to evaluate the effect of TW001 on oxidative stress biomarkers• to evaluate the safety of TW001 in patients with Alzheimer*s DiseaseSecondary objective:The secondary objective of the…
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.